Movement Alert｜GSK Rises 3.01% in Regular Trading, Positive Phase III Data for Hepatitis B Functional Cure Drug and Accelerated China Launch

Market Focus06-05 03:54

On June 5, GSK rose 3.01% in regular trading, trading at $51.22/share, with trading volume of $170 million.

The move was driven by positive Phase III clinical data for Bepirovirsen, GSK's hepatitis B functional cure candidate developed in collaboration with China Grand Pharmaceutical's subsidiary Chia Tai Tianqing. Data showed an overall functional cure rate of 19% after six months of treatment, with 26% in patients with low baseline viral activity and 35% in the Chinese subgroup with HBsAg≤1000 IU/mL, versus 0% for placebo.

Additionally, the drug has been resubmitted for marketing approval in China and accepted for priority review, with GSK expecting a regulatory decision from China's NMPA in the first half of next year. Bepirovirsen is also under review by regulators in the US, Europe, and Japan. Jefferies projects peak annual sales of $1.5 billion, while GSK's internal estimates are more optimistic, potentially exceeding $2.7 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109935081?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 03:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109935081","market":"hk","top_or_hot":-1,"title":"Movement Alert｜GSK Rises 3.01% in Regular Trading, Positive Phase III Data for Hepatitis B Functional Cure Drug and Accelerated China Launch","media":"Market Focus","content":"<p><p>On June 5, GSK rose 3.01% in regular trading, trading at $51.22/share, with trading volume of $170 million.</p><p>The move was driven by positive Phase III clinical data for Bepirovirsen, GSK's hepatitis B functional cure candidate developed in collaboration with China Grand Pharmaceutical's subsidiary Chia Tai Tianqing. Data showed an overall functional cure rate of 19% after six months of treatment, with 26% in patients with low baseline viral activity and 35% in the Chinese subgroup with HBsAg≤1000 IU/mL, versus 0% for placebo.</p><p>Additionally, the drug has been resubmitted for marketing approval in China and accepted for priority review, with GSK expecting a regulatory decision from China's NMPA in the first half of next year. Bepirovirsen is also under review by regulators in the US, Europe, and Japan. Jefferies projects peak annual sales of $1.5 billion, while GSK's internal estimates are more optimistic, potentially exceeding $2.7 billion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GSK Rises 3.01% in Regular Trading, Positive Phase III Data for Hepatitis B Functional Cure Drug and Accelerated China Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GSK Rises 3.01% in Regular Trading, Positive Phase III Data for Hepatitis B Functional Cure Drug and Accelerated China Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 03:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 5, GSK rose 3.01% in regular trading, trading at $51.22/share, with trading volume of $170 million.</p><p>The move was driven by positive Phase III clinical data for Bepirovirsen, GSK's hepatitis B functional cure candidate developed in collaboration with China Grand Pharmaceutical's subsidiary Chia Tai Tianqing. Data showed an overall functional cure rate of 19% after six months of treatment, with 26% in patients with low baseline viral activity and 35% in the Chinese subgroup with HBsAg≤1000 IU/mL, versus 0% for placebo.</p><p>Additionally, the drug has been resubmitted for marketing approval in China and accepted for priority review, with GSK expecting a regulatory decision from China's NMPA in the first half of next year. Bepirovirsen is also under review by regulators in the US, Europe, and Japan. Jefferies projects peak annual sales of $1.5 billion, while GSK's internal estimates are more optimistic, potentially exceeding $2.7 billion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"","article_id":"1109935081","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109935081","pubTimestamp":1780602852,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 5, GSK rose 3.01% in regular trading, trading at $51.22/share, with trading volume of $170 million.The move was driven by positive Phase III clinical data for Bepirovirsen, GSK's hepatitis B...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克"},"translate_title":"动静快讯|GSK常规交易涨3.01%，乙肝功能性治愈药物III期数据积极并加速在中国上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1},"content_text":"On June 5, GSK rose 3.01% in regular trading, trading at $51.22/share, with trading volume of $170 million.The move was driven by positive Phase III clinical data for Bepirovirsen, GSK's hepatitis B functional cure candidate developed in collaboration with China Grand Pharmaceutical's subsidiary Chia Tai Tianqing. Data showed an overall functional cure rate of 19% after six months of treatment, with 26% in patients with low baseline viral activity and 35% in the Chinese subgroup with HBsAg≤1000 IU/mL, versus 0% for placebo.Additionally, the drug has been resubmitted for marketing approval in China and accepted for priority review, with GSK expecting a regulatory decision from China's NMPA in the first half of next year. Bepirovirsen is also under review by regulators in the US, Europe, and Japan. Jefferies projects peak annual sales of $1.5 billion, while GSK's internal estimates are more optimistic, potentially exceeding $2.7 billion.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109935081","isCrawlerRequest":true}